Be part of the knowledge.™

Pathology and Laboratory Medicine

58

LikeLikedUnlike

31-45 of 59

MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 credits 10 episodes
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
advertisement
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
- Benjamin Levy, MD
  Peer
- Alexander Spira, MD, PhD, FACP
  Peer
0.25 credits
advertisement
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
- Helena Yu, MD
  Peer
0.25 credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
- Jyoti Patel, MD
  Peer
- Pasi Antero Jänne, MD, PhD
  Peer
0.50 credits
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
CME/CE
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
- William J. Gradishar, MD
  Peer
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended